...
机译:在体内ERK1 / 2报道中,记者预测模型模型和抗黑色瘤联合BRAF的抗性
Thomas Jefferson Univ Dept Canc Biol Philadelphia PA 19107 USA;
Thomas Jefferson Univ Dept Canc Biol Philadelphia PA 19107 USA;
Sidney Kimmel Canc Ctr Jefferson Div Biostat Philadelphia PA USA;
Thomas Jefferson Univ Dept Canc Biol Philadelphia PA 19107 USA;
Thomas Jefferson Univ Dept Canc Biol Philadelphia PA 19107 USA;
Univ Texas MD Anderson Canc Ctr Dept Melanoma Med Oncol Div Canc Med Houston TX 77030 USA;
Univ Penn Perelman Sch Med Dept Med Translat Med &
Human Genet Philadelphia PA USA;
Netherlands Canc Inst Div Mol Oncol &
Immunol Amsterdam Netherlands;
Netherlands Canc Inst Div Mol Oncol &
Immunol Amsterdam Netherlands;
Thomas Jefferson Univ Dept Canc Biol Philadelphia PA 19107 USA;
机译:在体内ERK1 / 2报道中,记者预测模型模型和抗黑色瘤联合BRAF的抗性
机译:多种癌症相关途径的活动与BRAF突变相关,并预测黑色素瘤细胞对BRAF / MEK抑制剂的耐药性
机译:在体内和离体中黑色素瘤中悖论和抗悖论破碎的BRAF抑制剂的反应和抗性
机译:黑色素瘤中BRAF抑制剂抗性的基因表达模型预测了新型组合疗法的药物重新培养候选者
机译:优化NRAS突变体黑素瘤耐久性和组合策略中的MEK抑制剂
机译:AT13387对HSP90的抑制作用延迟了对BRAF抑制剂的耐药性的出现并克服了在黑色素瘤模型中对BRAF和MEK双重抑制的耐药性
机译:在体内ERK1 / 2报道中,记者预测黑色素瘤联合BRAF和MEK抑制剂的响应和抵抗力